CD5 CAR T-Cells for Treatment of Patients with Relapsed/Refractory CD5 Expressing T-Cell Lymphoma Demonstrates Safety and Anti-Tumor Activity

被引：0
|
作者：
Hill, LaQuisa [1 ]
Rouce, Rayne Helen [1 ]
Smith, Tyler S. [1 ]
Yang, Lina [1 ]
Srinivasan, Madhuwanti [1 ]
Zhang, Huimin [1 ]
Perconti, Silvana [1 ]
Mehta, Birju [1 ]
Dakhova, Olga [1 ]
Randall, Josalind [1 ]
Grilley, Bambi [1 ]
Heslop, Helen E. [1 ]
Brenner, Malcolm K. [1 ]
Mamonkin, Maksim [1 ]
机构：
[1] Houston Methodist Hosp, Texas Childrens Hosp, Baylor Coll Med, Ctr Cell & Gene Therapy, Houston, TX 77030 USA
来源：
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION | 2020年 / 26卷 / 03期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
354
引用
收藏
页码：S237 / S238
页数：2
相关论文
共 50 条
  • [1] Safety and Anti-Tumor Activity of CD5 CAR T-Cells in Patients with Relapsed/Refractory T-Cell Malignancies
    Hill, LaQuisa C.
    Rouce, Rayne H.
    Smith, Tyler S.
    Yang, Lina
    Srinivasan, Madhuwanti
    Zhang, Huimin
    Perconti, Silvana
    Mehta, Birju
    Dakhova, Olga
    Randall, Josalind
    Grilley, Bambi J.
    Heslop, Helen E.
    Brenner, Malcolm K.
    Mamonkin, Maksim
    BLOOD, 2019, 134
  • [2] Early Signals of Anti-Tumor Efficacy and Safety with Autologous CD5.CAR T-Cells in Patients with Refractory/Relapsed T-Cell Lymphoma
    Rouce, Rayne H.
    Hill, LaQuisa C.
    Smith, Tyler S.
    Yang, Lina
    Boriskie, Blakely
    Srinivasan, Madhuwanti
    Zhang, Huimin
    Perconti, Silvana
    Mehta, Birju
    Dakhova, Olga
    Grilley, Bambi J.
    Heslop, Helen E.
    Brenner, Malcolm K.
    Mamonkin, Maksim
    BLOOD, 2021, 138
  • [3] CD5 CAR for the Treatment of T-Cell Malignancies
    Mamonkin, Maksim
    Brenner, Malcolm K.
    MOLECULAR THERAPY, 2015, 23 : S162 - S163
  • [4] Enhanced anti-tumor activity of CD5 CAR T cells manufactured with tyrosine kinase inhibitors in patients with relapsed/refractory T-ALL.
    Hill, LaQuisa C.
    Rouce, Rayne H.
    Smith, Tyler S.
    Boriskie, Blakely
    Srinivasan, Madhuwanti
    Thakkar, Sachin G.
    Zhang, Huimin
    Mehta, Birju
    Sritabal-Ramirez, Juntima
    Grilley, Bambi J.
    Heslop, Helen E.
    Brenner, Malcolm K.
    Mamonkin, Maksim
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [5] Mitigating the CD5 CAR-CD5 interaction enhances the functionality of CD5 CAR-T cells by alleviating the T-cell fratricide
    Ho, Lee Young
    Yu, Seung Rok
    Jeong, Hoon Jeong
    Lee, Hyeong Ji
    Cho, Hyeon Jeong
    Kim, Hyung Cheol
    CANCER RESEARCH, 2023, 83 (07)
  • [6] T-cells resist CD5 CAR mediated fratricide by continuously degrading CD5 protein
    Ma, Royce
    Popat, Divya
    Chaumette, Alex
    Carisey, Alexandre
    Brenner, Malcolm K.
    Mamonkin, Maksim
    JOURNAL OF IMMUNOLOGY, 2022, 208 (01):
  • [7] CD5 CAR T-Cells Avoid Self-Elimination by Continuously Degrading CD5 Protein
    Ma, Royce
    Popat, Divya
    Chaumette, Alex
    Carisey, Alexandre
    McKenna, Mary K.
    Srinivasan, Madhuwanti
    Watanabe, Norihiro
    Brenner, Malcolm K.
    Mamonkin, Maksim
    MOLECULAR THERAPY, 2021, 29 (04) : 36 - 36
  • [8] CLINICAL DEVELOPMENT OF A NOVEL CD5 KNOCKED OUT ANTI-CD5 CAR T CELL PRODUCT FOR T CELL LYMPHOMA
    Patel, R.
    Ghilardi, G.
    Porazzi, P.
    Yang, S.
    Qian, D.
    Zhang, Y.
    Pajarillo, R.
    Schuster, S.
    Barta, S.
    Nimmagadda, A.
    Snook, A.
    Siciliano, N.
    Ruella, M.
    CYTOTHERAPY, 2023, 25 (06) : S248 - S248
  • [9] CD5 Expression in Mature T Cell Lymphoma
    Cao, Miao
    Tavakkoli, Montreh
    Chong, Elise A.
    Carter, Jordan S.
    Ruella, Marco
    Landsburg, Daniel J.
    Nasta, Sunita D.
    Svoboda, Jakub
    Schuster, Stephen J.
    Barta, Stefan K.
    BLOOD, 2023, 142
  • [10] Phase I study of donor-derived CD5 CAR T cells in patients with relapsed or refractory T-cell acute lymphoblastic leukemia.
    Pan, Jing
    Tan, Yue
    Shan, Lingling
    Deng, Biping
    Ling, Zhuojun
    Song, Weiliang
    Feng, Xiaoming
    Hu, Guang
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
12345